1.  Klein D. Delineation of two drug responses for anxiety syndromes. Psychopharmacologia  1964; 5: 397-408.

2.  Zitrin CM, Klein DF, Woerner MG. Treatment of phobias . Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatr 40:125-138, 1983.

3.  Uhlenuth EH, Mastuzas W, Glass RM, Easton C. Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989; 17: 261-270.

4.  Andersch S, Rosenberg NK, Kullingsjo H, Ottoson JQ, Hanson L, Lorentzen K, Mellergard M, Rasmussen S, Rosenberg R: Efficacy and safety of alprazolam, imipramine, and placebo in treating panic disorder: a Scandinavian multicenter study. Acta Psychiatr Scand Suppl 1991; 365:18-27.

5.  Mavissakalian M, Perel JM: Imipramine in the treatment of agoraphobia: dose response relationships. Am J Psychiatry 1985; 142: 10032-1036.

6.  Mavissakalian M, Perel JM: Imipramine dose response relationships in panic disorder with agoraphobia. Arch Gen Psychiatry 1989;46:127-131.

7.  Woods S, Nagy L, Koleszar AS, Krystal JH, Heninger GR, Charney DS: Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J Clin Psychopharmacol 1991; 12:32-38.
8.  Mellergard M, Lorentzen K, Bech P, Ottoson JQ, Rosenberg R: A trend analysis of changes during treatment of panic disorder with alprazolam and imipramine. Acta Psychiatr Scand Suppl 1991; 365:28-32.

9.  Johnson D, Troyer I, Whitsett S: Clomipramine treatment of agoraphobic women: an eight week controlled trial. Archives of General Psychiatry 1988;45:453-459.

10. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: A placebo controlled trial. Journal of Clinical Psychopharmacology 1992;12: 251-261.

11. Cassano G, Petracca A, Perugi G, Nisita C, Musetti L, Mengali F, McNair DM: Clomipramine for panic disorder,I: the first 10weeks of a long term comparison with imipramine. J Affect Disord 1988;14:123-127.

12. Papp L, Schneier F, Fyer A, Liebowitz M, Gorman J, Coplan J, Campeas R, Fallon B, Klein D. Clomipramine treatment of panic disorder: Pros and Cons. J Clin Psychiatry 1997; 58:423-425.

13. Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, Hillmer-Vogel U, Ruther E. Comparison of aerobic exercise, clomipramine and placebo in the treatment of panic disorder. Am J Psychiatry  1998; 155(5):603-9.

14. Kalus O, Asnis G, Rubinson E, Friedman J, Iqbal N,Grosz D, van Praag H, Cahn W. Desipramine treatment in panic disorder. Journal of Affect Disord 1991; 21:230-244.

15. Lydiard R, Morton W, Emmanuel N, Zealberg J, Laraia M, Stuart G, O’Neil P, Ballenger J: Preliminary report: placebo controlled, double blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 1993;29:183-188.

16. Munjack D, Usigli R, Zulueata A, Crocker B, Adatia N, Buckwalter J, Baltazar P, Kurvnink W, Inglove H, Kelly R. Nortriptyline in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1988; 8: 204-207.

17. Den Boer J, Westenberg H, : Effect of a sertotonin and noradrenaline uptake inhibitor in panic disorder: a double blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3: 59-74.

18. Zitrin C, Klein D, Woerner M. Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry 1980; 37: 63-72.

19. Mavissakalian M, Perel J. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level response relationships. Am J Psychiatry 1995;152:673-682.

20. Mavissakalian M, Perel J. Imipramine in the treatment of agoraphobia: Dose response relationships. Am J Psychiatry 142: 1032-1036, 1985.

21. Practice Guidelines for the Treatment of Panic Disorder. Am J Psychiatry 1998 (suppl) May.

22. Mavissakalian M, Perel J. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1992;49:318-323.

23. Mavissakalian M, Perel J. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry 1992;149:1053-1057.

24. Curtis G, Massana J, Udina C, Ayuso J, Cassano G, Perugi G. Maintenance drug therapy of panic disorder. J Psychiatr Res 1993;27:127-142.

25. Gorman J, Liebowitz M, Fyer A. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987;7:329-339.

26. Schneier F, Liebowitz M, Davies S. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-121.

27. Bystritsky A, Rosen R, Murphy K, Bohn P, Keys S, Vapnick T. Double blind trial of desipramine versus fluoxetine in panic patients. Anxiety 1994;1:281-190.

28. Lydiard R, Pollack M, Judge R, Michelson D, Tamura R. Fluoxetine in panic disorder: a placebo controlled study. Presented at the Xth Congress of the European College of Neuropsychopharmacology, September 1997, Venice, Italy.

29. Gorman J, Wolkow W. Sertraline as a treatment for panic disorder. Presented at the annual meeting of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), June 1994.

30. Duboff E, England D, Ferguson J. Sertraline in the treatment of panic disorder. Presented at the VIIIth Congress of the European College of Neuropsychopharmacology. September 30-

October 4^th, 1995, Venice Italy.

31. Wolkow R, Apter J, Clayton A. Double blind flexible dose study of sertraline and placebo in patients with panic disorder. Presented at the Annual Meeting of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), June, 1996.

32. Ballenger J, Wheadon D, Steiner M, Bushnell W, Gergel I. Double blind, placebo controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42.

33. Burnham D, Steiner M, Gergel I, Oakes R, Bailer D, Wheadon D. Paroxetine long term efficacy and safety in panic disorder and prevention of relapse: A double blind study. Presented at the American College of Neuropsychopharmacology, December 11-15, 1995, San Juan, Puerto Rico.

34. Oehrberg S, Christiansen P, Behnke K. Paroxetine in the treatment of panic disorder: A randomised placebo controlled study. Br J Psychiatry 1995;167:374-379.

35.Lecrubier Y, Bakker A, Dunbar G, Judge R and the Collabo Collaborative Panic Study Investigators. Long term evaluation of paroxetine, clomipramine, and placebo in rative Paroxetine Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 1997;95:145-152.

36. Lecrubier Y, Judge R and the Collaborative Paroxetine Panic Study Investigators. Long term evaluation of paroxetine, clomipramine, and placebo in panic disorder. Acta Psychiatr Scand 1997;95;153-160.

37.  Black D, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50.

38. Sharp D, Power K, Simpson R. Fluvoxamine, placebo and cognitive behavior therapy used alone and in combination in the treatment of panic disorder and agoraphobia. J Anxiety Disord 1996;10:219-242.

39. Den Boer W, Kahn R. Effect of serotonin uptake inhibitors in anxiety disorders: A double blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987; 2:21-32.

40. Den Boer J, Van Vliet I, Westenberg H. A double blind comparative study of fluvoxamine and brofaromine in panic disorder. Clin Neuropharmacol 1992;15(suppl):91B

41.den Boer J, Westenberg H. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 1990;102:85-94.

42. Bakish D, Hooper C, Filteau M. A double blind placebo controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996;32:135-141.

43.Nair N, Bakish D, Saxena B, Amin M, Schwartz G, West T. Comparison of fluvoxamine, imipramine and placebo in the treatment of outpatients with panic disorder. Anxiety 1996;2:192-198.

44. Klerman G. Overview of the Cross National Collaborative Panic Study. Arch Gen Psychiatry 1988; 45: 407-412.

45. Ballenger J, Burrows G, Dupont R, Lesser I, Noyes R, Pecknold J, Rifkin A, Swinson R. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short term treatment. Arch Gen Psychiatry 1988; 45:413-422.

46. Cross National Collaborative Panic Study Second Phase Investigators. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo. Br J Psychiatry 1992;160:191-202.

47. Marks IM, Greist J, Basoglu M. Comment on the second phase of the  Cross National Panic Study. Br J Psychiatry 160 : 202-205, 1992.

48. Dunner DL, Ishiki D, Avery D, Wilson L, Hyde T. Effect of alprazolam and diazepam in anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986;45:407-412.

49. Tesar G, Rosenbaum J, Pollack J, Otto M, Sachs G, Herman J, Cohen L, Spier S. Double blind, placebo controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69-76.

50. Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder I: results of a prospective, placebo controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993;50:51-60.

51. Dager S, Roy- Byrne P, HendricksonH, Cowley D, Avery D, Hall K, Dunner D. Long term outcome of panic states during double blind treatment and after withdrawal of alprazolam and placebo. Ann Clin Psychiatry 1992;4:251-258.

52. Chouinard G, AnnableL, Fontaine R, Solyom L. Alprazolam in the treatment of generalized anxiety and panic disorders: a double blind placebo controlled study. Psychopharmacology 1982;77:229-233.

53. Rosenbaum J, Moroz G, Bowden C. Clonazepam in the treatment of panic disorder with and without agoraphobia: a dose response study of efficacy, safety and discontinuance. J Clin Psychopharmcol 1997.

54. Tesar G, Rosenbaum J, Pollack M, Otto M, Sachs G, Herman J, Cohen L, McNamara M, Spier S. Double blind placebo controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69-76.

55. Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani V. Lorazepam versus alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990;23:90-93.

56. Charney D, Woods S. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989;50:418-423.

57. Noyes R, Burrows G, Reich J, Judd F, Garvey M, Norman T, Cook B, Marriott P. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996; 57:349-355.

58. Dunner D, Ishiki D, Avery D, Wilson L, Hyde T. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. J Clin Psychiatry 1986;47:458-460.

59. Rickels K, Schweizer E, Weiss S, Zavodnick S. Maintenance drug treatment for panic disorder. Short and long term outcome after drug taper. Arch Gen Psychiatry 1993;50:61-68.

60. Fyer A, Leibowitz M, Gorman J, Campeas R, Levin A, Davies S, Goetz D, Klein D. Discontinuation of alprazolam treatment in panic patients. Am J Psychiatry 1987;144:303-308.

61.Noyes R, Garvey M, Cook B, Suelzer M. Controlled discontinuation of benzodiazepine treatment for patient with panic disorder. Am J Psychiatry 1991;148:517-523.

62. Salzman C. Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity and abuse. J Psychiatr Res 1993;27:97-110.

63.Benzodiazepine Dependence, Toxicity and Abuse: A task force report of the American Psychiatric Association. Washington DC, APA 1990.

64. Uhlenuth E, Matuzas W, Glass R, Easton C. Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989;17:261-270.

65. Lydiard R, Lesser I, Ballenger J, Rubin R, Laraia M, Dupont R. A fixed dose study of alprazolam 2 mg, alprazolam 6mg and placebo in panic disorder. J Clin Psychopharmacol 1992;12:96-103.

66. Pollack M, Otto M, Tesar G. Long term outcome after acute treatment with clonazepam and alprazolam for panic disorder. J Clin Psychopharmacol 1993; 13: 257-263.

67.

68. DuPont R, Swinson R, Ballenger J. Discontinuation of alprazolam after long term treatment of panic related disorders. J Clin Psychopharmacol 1992; 12:352-354.

69. Rickels K, Schweizer E, Weis S. Maintenance drug treatment for panic disorder II. Short and long term outcome after drug taper. Arch Gen Psychiatry 1993; 50: 61-68.

70. Lepola U Rimon  R, Riekkinen P. Three year follow up of patients with panic disorder after short term treatment with alprazolam and imipramine. Int Clin Psychopharmacol 1993; 8: 115-118. 

71. Sheehan D, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37;51-59.

72. Buiges J, Vallego J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987;48:55-59.

73. Bakish D, Saxena B, Bowen R, D’Souza J. Reversible monoamine oxidase inhibitors in panic disorder. Clin Neuropsychopharmacol 1993; 16(suppl):77-82.

74. Garcia-Borreguero D, Lauer C, Ozdaglar A, Wiedemann K, Holsboer F, Krieg J. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase A. Pharmacopsychiatry 1992; 25:261-264.

75. Zajecka J. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry; 57(suppl)10-14.

76. DeMartinis N, Schweizer E, Rickels K. An open label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996;57:245-248.

77. Pollack M, Worthington J, Otto M, Maki K, Smoller J, Manfro G, Rudolph R, Rosenbaum J. Venlafaxine for panic disorder: results from a double blind placebo controlled study. Psychopharmacol Bull 1996;32:667-670.

78. Geracioti J. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995;56:408-410.

79. Papp L, Sinha S, Coplan J, Martinez J, Amchin J, Gorman J. Low dose Venlafaxine treatment for panic disorder. Psychopharmacol Bull 1998; 34(2) 207-209.

80.Klein E, Uhde T. Controlled study of verapamil for treatment of panic disorder.

Am J Psychiatry 1988;9:22-27.

81. Goldstein J. Calcium channel blockers in the treatment of panic disorder. J Clin Psychiatry 1985;46:546.

82. Gibbs D. Hyperventilation induced cerebral ischemia in panic disorder and effect of nimodipine. Am J Psychiatry 1992; 149:1589-1591.

83. Liang K, Lee E. Intraamygdaloid injections or corticotropin releasing factor facilitate avoidance learning and reduce exploratory behavior in rats. Psychopharmacology 1988;96:232.

84. Moreau J, Kilpatrick G, Jenck F. Urocortin, a novel neuropeptide with anxiogenic like properties. Neuroreport 1997;8:1697-701.

85. Pich E, Koob G, Sattler S, Menzaghi F, Heilig M, Heinrichs S, Vale W, Weiss F. Stress induced release of corticotropin releasing factor in the amygdala by in vivo microdialysis. Soc Neurosci Abstr 1992;18:535.

86. Kalin N, Sherman J, Takahashi L. Antagonism of endogenous CRH systems attenuates stress induced freezing behavior in rats. Brain Res 1988;457:130.

87. Kask A, Rago L, Harro J. Alpha helical CRF 9-41 prevents anxiogenic like effects of NPY Y1 receptor antagonist BIBP3226 in rats. Neuroreport 1997;8:3645-7.

88. Sarnyai Z. Neurobiology of stress and cocaine addiction . Studies on corticotropin releasing factor in rats, monkeys and humans. Annals of New York Academy of Sciences 1998;851:371-387.

89. Boadle-Biber M, Singh V, Corley K, Phan T, Dilts R. Evidence that corticotropin releasing factor  within the extended amygdala mediates the activation of tryptophan hydroxylase produced by sound stress in the rat.  Brain Res 1993;628:105.

90. Smagin G, Harris R, Ryan D. Corticotropin releasing factor receptor antagonist infused into the locus ceruleus attenuates immobilization stress induced defensive withdrawal in rats. Neuroscience letters 1996; 220:167-170.

91. Hasserhorl R, Jentjens O, De Souza Silva M, Tomaz C, Huston J. Anxiolytic action of neurokinin substance P administered systemically or into the nucleus basalis magnocellularis region. Eur J Pharmacology, 1998; 354: 123-33.

92. Weiss D, Hirt R, Tarcic N, Berzon Y, Ben Zur H, Breznitz S, Glaser B, Grover N, Baras M, O’Dorisio T. Studies in psychoneuroimmunology: psychological, immunological and neuroendocrinological parameters in Israeli Civilians during and after a period of Scud missile attacks. Behavioral Medicine, 1996; 22:5-14.

93. File S. Anxiolytic action of a neurokinin 1 receptor antagonist in the social interaction test. Pharmacol Biochem Behav 1997;58:747-52.

94. Kramer M, Cutler N Feighner J et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281:1640-5.

95. Shear K, Brown T, Barlow D, Money R, Sholomskas D, Woods S, Gorman J, Papp L. Multicenter Collaborative Panic Disorder Severity Scale. Am J Psychiatry 1997; 154:1571-1575.

96. Tiffon L, Coplan J, Papp L, Gorman J. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Psychiatry 1994;55:66-69.

97. Ledoux JE, Iwata J, Cicchetti P Reis D. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. J Neuroscience. 1988; 8: 2517-2519

98. Davis M. The role of the amygdala in fear and anxiety. Ann Rev Neurosci 1992; 15: 353-375.

99. Takeuchi Y, Mclean J Hopkins D. Reciprocal connections between the amygdala and parabrachial nuclei: Ultrastructural demonstration by degeneration and axonal transport of horseradish peroxidase in the cat. Brain Res 1982; 239: 538-588.

100. Price J, Amaral D. An autoradiographic study of the projections of the central nucleus of the monkey amygdala. J Neurosci 1981; 1: 1242-1259.

101. Cedarbaum J, Aghajanian G. Afferent projections to the rat locus ceruleus as determined by a retrograde tracing technique. J Comp Neurol 1978; 178: 1-16.

102. Dunn JD, WhitenerJ . Plasma coriticosterone responses to electrical stimulation of he amygdaloid complex: cytoarchitectural specificity. Neuroendocrinology 1986; 42: 211-217.

103. De Oca B, DeCola J, Maren S, Fanselow M. Distinct regions of the periaqueductal gray are involved in the acquisition and expression of defensive responses. J Neurosci 1998; 18 (9): 3426-3432.

104. De Olmos J. Amygdaloid nuclear gray complex. In: Paxinos G, ed. The Human Nervous System. San Diego: Academic Press, pp.583-710, 1990.

105. Tork I, Hornung J. Raphe nuclei and the serotonergic system. In: Paxinos G, ed. The Human Nervous System. San Diego: Academic Press, pp. 1001-1022, 1990.

106. Aston- Jones G, Akaoka H, Charletty P, Chouvet G. Sertotonin selectively attenuates glutamated evoked activation of noradrenergic locus ceruleus neurons. J Neurosci 1991; 11: 760-769.

107. Viana M, Graeff F, Loschmann P. Kainate microinjection into the dorsal raphe nucleus induces 5-HT release in the amygdala and periaqueductal grey. Pharmacol Biochem Behav 1997; 58(1): 167-172.

108. Brady L, Gold P, Herkenham M.  The antidepressants fluoxetine, idazoxam and phenelzine alter corticotropin releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992; 572: 117-125.

109. Elkabir D, Wyatt M,  Velucci S, Herbert J. The effects of separate or combined infusions of corticotropin releasing factor and vasopressin either intravenously or into the amygdala on aggressived  and investigative behavior in the rat. Reg Peptides 1990; 28: 199-214.

Back to Chapter